Skip to main content

Table 3 Continuous outcomes

From: N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial

Outcome Placebo (n = 40) NAC + DFX (n = 40) P value
Time to develop AKI, days, median (IR) 1.5 (1–4.5) 1 (1–2) 0.53
AKI duration, days, median (IR) 0.5 (0–6) 1 (0–2) 0.04
ICU-free days to day 28, median (IR) 18 (2–23) 15 (2–23) 0.68
Hospital length of stay, days, median (IR) 10 (6–22) 12 (7–18) 0.58
Creatinine level at discharge, mg/dL, median (IR) 1.1 (0.6–1.8) 0.7 (0.5–1.2) 0.05
SOFA score day 3, median (IR) 9 (4–14) 6.5 (5–10) 0.28
Renal SOFA score day 3, median (IR) 3 (0–3) 1 (0–2.2) 0.10
  1. NAC + DFX N-acetylcysteine plus deferoxamine, ICU intensive care unit, AKI acute kidney injury
  2. SOFA Sequential Organ Failure Assessment, IR interquartile range